display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic, hormone-sensitive prostate cancer
metastatic, hormone-sensitive prostate cancer
enzalutamide
enzalutamide plus ADT ENZAMET ARCHES

Study type: